Last reviewed 26 August 2026
Every UK supplier publishes a “most popular peptides” list, and almost every one of them is a sales page wearing a survey’s clothes. This one is built differently: it synthesises the demand signals that are actually published — two UK suppliers’ own best-seller and interest rankings, our first-party search data, and national enforcement figures as a proxy for the demand nobody prints — and it says plainly where each signal comes from and what it cannot tell you. Popularity is a fact about buyers. It is not a fact about evidence, and nothing below is a statement about what any compound does.
How this list is put together
Three signals, weighted in this order. First, published demand rankings: Imperial Peptides UK publish a best-seller list based on product demand within our own catalogue during 2026
, and Tide Labs publish a most-popular list for 2025 — two independent catalogues, and they largely agree. Second, our own search data: Google Search Console shows which entries in our compound library UK searchers actually reach, which adds compounds the seller lists miss. Third, for one category, enforcement data: the HPRA’s detention figures are the only published measure of demand for the prescription-medicine class, and they are startling. What this list deliberately excludes is our own sales ledger — the site is weeks old, and a demand ranking built on a young dataset would be exactly the kind of dressed-up claim this article exists to avoid.
The consensus six
Where the published UK lists converge. Order within this group follows the combined rankings; the difference between adjacent places is small and shifts month to month.
1. BPC-157. A synthetic 15-amino-acid sequence derived from a fragment of the human gastric protein BPC, studied in tissue-repair models — and at or near the top of every UK list published (Tide Labs go as far as nicknaming it “The Wolverine Peptide”). The evidence record, with every citation resolved, is in the library entry; the vial is BPC-157 10mg.
2. TB-500. The acetylated 17–23 fragment (LKKTETQ) of the human protein thymosin β4, studied in cell-migration models. Almost always discussed alongside BPC-157 — the two share no chemistry, as we’ve set out in detail — and the research community’s name for the combination is the “Wolverine” blend. Library: TB-500; vials: TB-500 5mg and the BPC-157 + TB-500 blend.
3. GHK-Cu. A naturally occurring copper-binding tripeptide, studied in skin-biology and wound-model research — and the number-one seller in Imperial’s 2026 list, which matches what we see: it anchors the UK’s skin-research demand. Library: GHK-Cu; vials: 50mg and 100mg.
4. Ipamorelin. A pentapeptide growth-hormone secretagogue, studied for its receptor selectivity relative to the older GHRPs. Library: Ipamorelin; vial: Ipamorelin 10mg.
5. CJC-1295. A GHRH analogue — the “with DAC / without DAC” distinction matters and is set out in the library entry — most often paired with ipamorelin in secretagogue research; the UK lists rank the No-DAC form. We stock the pairing as a single blended vial: CJC-1295 + Ipamorelin 10mg.
6. MOTS-C. A 16-residue mitochondrial-derived peptide, studied in metabolic and mitochondrial research — sixth in Imperial’s list and a fixture of the mitochondrial cluster our library covers as a group. Library: MOTS-C; vial: MOTS-C 20mg.
What our own search data adds
Search Console shows which library entries people actually arrive at, and it surfaces demand the seller lists don’t print. Cagrilintide — a long-acting amylin analogue — is among the most-reached entries in our library and interest is visibly rising; we stock it as Cagrilintide 10mg. Kisspeptin-10 (reproductive-axis signalling research) and sermorelin (a GHRH 1–29 analogue, library-only here) both draw steady search interest. MK-677 is searched heavily — it is an oral, non-peptide secretagogue, which is why it appears in our library and not our fridge. The Semax/Selank pair pulls a persistent nootropic-research audience (compared here), and 5-Amino-1MQ — a small-molecule NNMT inhibitor, on every “peptide” list despite not being one — earns page-one search placement of its own. Interest, note, is not the same thing as availability: where an entry is library-only, that is a deliberate stocking decision, not an oversight.
The elephant: the GLP-1 class
Measured by raw search interest, nothing above competes with the GLP-1 class — semaglutide, tirzepatide, retatrutide and their relatives dominate what people type. The only published national measure of that demand is an enforcement statistic: the HPRA detained 48,752 GLP-1-class units entering Ireland in 2025, up from 1,582 the year before. These compounds are prescription-medicine actives, and this is where an honest popularity list has to break with the market: they belong in a reference library, and they do not belong in a research catalogue — our reasoning is published. Any list that ranks them alongside laboratory reagents is telling you something important about the seller.
What a list like this cannot tell you
Demand is a lagging record of attention, not a measure of evidence. The compounds above span the whole range of the evidence spectrum — from substances with published human trials to substances documented only in cell culture — and the place to see that spectrum honestly is each compound’s library entry, where the evidence panel and every cited study are checkable. Rankings also drift: this page states its sources and its date, and we will re-review it as the signals change. Everything NovoVita supplies is for laboratory research use only and is not for human or veterinary use; a library entry is documentation of the published record, not a product.
Sources
- Imperial Peptides UK, Best Selling Research Peptides in 2026 (25 June 2026) — their own-catalogue demand ranking, quoted above.
- Tide Labs, Most Popular Peptides in the UK 2025 (updated 16 November 2025).
- HPRA, Over 750,000 units of illegal medicines detained by the HPRA in 2025 (24 March 2026) — the GLP-1 detention figures.
- NovoVita Search Console data, 28-day window to 25 August 2026 — first-party search-arrival data for the compound library, described in the text.